Return to Listing

6 result(s) for XTANDI

PI Name Protocol # Title
Joshi Alumkal IRB00010241 Molecular Mechanisms Underlying Tumor Progression Despite Enzalutamide Treatment
Julie Graff IRB00011025 PVAMC / OHSU J: Addition of Pembrolizumab Upon Progression on Enzalutamide in men with mCRPC
Julie Graff IRB00011227 VA/OHSU (J): A Phase I/II Trial of Concurrent Chemohormonal Therapy Using Enzalutamide (MDV-3100) and Cabazitaxel in Patients with Metastatic Castration Resistant Prostate Cancer
Arthur Hung IRB00011268 Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide (MDV3100) in Men with High-Risk PSA-Recurrent Prostate Cancer after Radical Prostatectomy
Gina Vaccaro STUDY00015077 9785-CL-3021: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Enzalutamide in Subjects with Advanced Hepatocellular Carcinoma
Tomasz Beer STUDY00015561 A Phase Ib/II, Multicentre, Open Label, Randomised Study of BI 836845 in Combination with Enzalutamide, versus Enzalutamide alone, in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Following Disease Progression on Docetaxel-Based Chemotherapy and Abiraterone. Protocol 1280.8

You may also qualify for Phase 1 Program trials.

For more information:
Call: 503-494-1080